Hybrid Nanoparticles: The Drug Delivery System for the Future

During the last two decades, the field of nanotechnology has blossomed, unfolding at such a rate that it has been drastically and directly impacting different fields, specifically medicine, since that time. Among the most exciting developments is the creation of hybrid nanoparticles, a class of engineered particles that coalesce distinctive properties from distinct materials in combination with embodied features to simulate multifunctional drug delivery systems. Such hybrid nanoparticles can potentially overcome the limitations of conventional drug delivery, including poor bioavailability, non-specific targeting, and adverse side effects. The wide diversity of materials like lipids, polymers, metals, and organic molecules that been incorporated into a single nanoparticle brings about new approaches toward precise, controlled, and efficacious drug delivery. The current article attempts to project in an array the progress made in hybrid nanoparticle technology as the future of drug delivery systems.

Concept of Hybrid Nanoparticles

Basically, hybrid nanoparticles are designed by a combination of two or more types of materials at the nanoscale that generates a composite structure where the strengths of each component can be harnessed. The combination of materials is generally done based on the concept that there are some developed functionalities that cannot be achieved with single-component nanoparticles. An example of such a hybrid nanoparticle includes a polymeric core used for the encapsulation of a drug, a lipid layer for biocompatibility, and a metallic envelope used for imaging. Targeted nanoparticles are designed to fit specific therapeutic needs, making them quite versatile tools in the medicine domain.

Yearwise Publication Trend on drug delivery

Find publication trends on relevant topics

Advantages of Hybrid Nanoparticles in Drug Delivery

Better bioavailability of drugs is one of the key advantages of hybrid nanoparticles in drug delivery. Drugs generally considered to have poor bioavailability, a major concern in drug delivery, are hydrophobic drugs with poor water solubility. These hybrid nanoparticles encapsulate such drugs in their shells, presenting them to the body with better solubility and, hence, better absorption. Further, targeting ligands that recognize cell types, such as cancerous cells, can be attached to the surface of the nanoparticle in order to ensure delivery of the drug precisely to the desired cell.

It can also regulate drug delivery. Some hybrid nanoparticles have the ability to trigger the release of their cargo by being either pH-responsive, temperature-responsive, or sensitive to enzymatic activity. In such cases, this release-on-demand mechanism is likely to be very beneficial for chemotherapy. To give a high dose of toxic drugs at the site of the tumor while sparing healthy tissue requires quite the opposite criteria in this line of treatment.

Recent advances in microfluidic technologies have significantly contributed to the synthesis of hybrid nanoparticles. Microfluidics allows high control over the mixing of materials to yield nanoparticles that are both uniform in size and composition. In line with this, within the same order of variation, it enables a high reproducibility of hybrid nanoparticles with tunability, which is key to attaining a clinically translatable scale.

One of the most striking developments in this regard is the invention of lipid-polymer hybrid nanoparticles. They combine the stability and drug-carrying capacity of polymers with the biocompatibility and targeting ability of lipids. A layer of lipids on their surface protects not only the polymeric core of the nanoparticles but also provides the means for attaching targeting ligands that enhance the specificity of drug delivery.

Yet another way of utilizing quantum dots is in hybrid nanoparticles. Quantum dots are very small, effectively a small-sized semiconductor particle with a couple of unique optical properties; one of them is fluorescence, which can be used for imaging. Researchers used a multifunctional system by loading quantum with hybrid nanoparticles, thereby achieving drug delivery in the body and tracking the drug’s distribution at the site of interest by imaging. This ability is highly useful in cancer treatment, and the localization and efficiency of the therapy are very desirable.

Therapeutic Applications in Cancer

Hybrid nanoparticles have excellent possibilities for therapeutic applications in cancer. Most of the major problems in cancer chemotherapy are directly or indirectly related to the loss of selective drug uptake in a tumor, which leads to severe side effects. Hybrids avoid this problem and serve as carriers for good drug delivery. For instance, engineering lipid-polymer hybrid nanoparticles to deliver chemotherapy drugs specifically to tumor cells might reduce side effects on healthy tissues. The lipid layer can be modified with ligands that interact with receptors overexpressed on the cancer cells, ensuring that the nanoparticles preferentially accumulate in the tumor.

Besides targeted delivery, hybrid nanoparticles can be designed for combination therapy, where two or more drugs are delivered in a single system. This is particularly suitable in the treatment of cancer, when multiple drugs act by different mechanisms to achieve an overall therapeutic effect. Hybrid nanoparticles can load several drugs into their layers or compartments to be sure that each drug release occurs at the correct time and location.

A photo-thermal therapy application is particularly promising, for example, through the use of hybrid nanoparticles that can convert light into heat and, in turn, kill cancer cells. An example of an efficient absorber of light that, in turn, produces heat is gold nanoparticles. Constructing the gold nanoparticles in a hybrid setting with a polymeric drug carrier will have a mode of administration of the chemotherapy drug with a way of locally heating the target to increase the effectiveness of the treatment.

Recent Publications on drug delivery

Find publications on relevant topics

Challenges and Future Directions

Despite great advances in the development of hybrid nanoparticles for drug delivery, many challenges remain. The first and foremost challenges in developing such nanoparticles are related to their stability within the circulatory blood. Hybrid nanoparticles need to be stable enough so that they survive in the blood long enough to reach the target site and successfully release the payload. This evidently demands well-designed nanoparticle components and surface modifications that preclude premature degradation or clearance through host immunological mechanisms.

Another problem when working with hybrid nanoparticles is that some of the materials used for production can be of a toxic nature. Although biocompatibles are usually represented by lipids and polymers, metals or other inorganic components can make a hybrid more toxic. Thus, it is very important to assess the safety of such materials and develop strategies that enable the minimization of adverse effects.

Hybrid nanoparticles for drug delivery hold a promising future. With the advancement of material science along with nanotechnology and microfluidics, development has to be even more precise with advanced functionalities at the cost of high throughput. As a matter of fact, researchers are investigating new stimuli-responsive biomaterials manifested by a change in pH or temperature, leading to better precision for drug delivery.

Furthermore, hybrid nanoparticles are now gaining increasing interest in personalized medicine. Such individualization in the composition and structure of nanoparticles, according to one patient’s needs, may prove advantageous in correlated and safer administrations. This approach might be particularly valuable in the case of cancer therapy, where the heterogeneity of the tumors often requires a personalized treatment strategy.

Conclusion

New-generation hybrid nanoparticles in the drug delivery system represent a potential approach for overcoming the many limitations of the conventional approach. By combining different materials, these nanoparticles can lead to functionalities beyond the limits of single-component systems, such as targeted delivery, controlled release, and multifunctionality. The adoption of state-of-the-art technologies, including microfluidics, has further enhanced the precision and scalability of the production of hybrid nanoparticles, thus allowing this process to have great potential for clinical applications. The field of hybrid nanoparticle research is burgeoning, and in the future, this technology may come to be primarily used in curing cancer and other critical diseases.

References

  1. Shepherd, S.J., Warzecha, C.C., Yadavali, S., El-Mayta, R., Alameh, M.G., Wang, L., Weissman, D., Wilson, J.M., Issadore, D. and Mitchell, M.J., 2021. Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device. Nano letters21(13), pp.5671-5680.
  2. Chai, Y., Wang, Y., Li, B., Qi, W., Su, R. and He, Z., 2021. Microfluidic synthesis of lignin/chitosan nanoparticles for the pH-responsive delivery of anticancer drugs. Langmuir37(23), pp.7219-7226.
  3. Fatima, H., Charinpanitkul, T. and Kim, K.S., 2021. Fundamentals to apply magnetic nanoparticles for hyperthermia therapy. Nanomaterials11(5), p.1203.
  4. Balachandran, Y.L., Li, X. and Jiang, X., 2021. Integrated microfluidic synthesis of aptamer functionalized biozeolitic imidazolate framework (BioZIF-8) targeting lymph node and tumor. Nano Letters21(3), pp.1335-1344.
  5. Rodrigues, R.O., Sousa, P.C., Gaspar, J., Bañobre‐López, M., Lima, R. and Minas, G., 2020. Organ‐on‐a‐chip: A preclinical microfluidic platform for the progress of nanomedicine. Small16(51), p.2003517.
  6. Li, X., Zha, M., Li, Y., Ni, J.S., Min, T., Kang, T., Yang, G., Tang, H., Li, K. and Jiang, X., 2020. Sub‐10 nm Aggregation‐Induced Emission Quantum Dots Assembled by Microfluidics for Enhanced Tumor Targeting and Reduced Retention in the Liver. Angewandte Chemie International Edition59(49), pp.21899-21903.
  7. Ghasemi Toudeshkchouei, M., Zahedi, P. and Shavandi, A., 2020. Microfluidic-assisted preparation of 5-fluorouracil-loaded PLGA nanoparticles as a potential system for colorectal cancer therapy. Materials13(7), p.1483.
  8. Wei, W., Sun, J., Guo, X.Y., Chen, X., Wang, R., Qiu, C., Zhang, H.T., Pang, W.H., Wang, J.C. and Zhang, Q., 2020. Microfluidic-based holonomic constraints of siRNA in the kernel of lipid/polymer hybrid nanoassemblies for improving stable and safe in vivo delivery. ACS applied materials & interfaces12(13), pp.14839-14854.

Top Experts on “drug delivery